 MONTREAL and CHARLOTTE, N.C. , March 23, 2020 CNW -- Milestone Pharmaceuticals Inc. MIST, a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced topline results from its Phase 3, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of its investigational new drug, etripamil nasal spray, the Companys novel short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia PSVT. The NODE-301 trial, which enrolled a total of 431 patients across 65 sites in the U.S. and Canada , is an event-driven Phase 3 efficacy trial of etripamil for terminating supraventricular tachycardia SVT episodes in the at-home setting. 